BioSpace News Archive

The Company’s management will also host a conference call on the same day at 8:30 a.m. EST.

To join the call, please dial-in at (855) 465-0180 (conference ID: 9796968).

The Company’s Phase 2b clinical trial of Prurisol, enrolling a total of 199 patients, remains on-track for completion in December.

The Company will host a conference call to discuss the financial results.

“Following another record quarter, with double-digit revenue and profit growth, we are well positioned to finish 2017 strongly and continue our momentum into 2018,” said Matthijs Glastra, CEO.

DURECT Corporation today announced financial results for the three months ended September 30, 2017 and provided a corporate update.

Synthetic Biologics today provided an operational update and reported financial results for the three months ended September 30, 2017.

The completion of these transactions improves Windtree’s balance sheet and better positions the Company to raise the capital needed to fund continued development of AEROSURF for RDS and potentially its pipeline of surfactant products utilizing its proprietary KL4 surfactant and aerosol device technologies.

The recent order of GlucoTrack, in the amount of US$460,000, was a re-order from an existing customer and represents a nearly two-fold increase from the original order.

An abstract of the Phase Ia trial results was posted today on the ASH website in advance of a poster presentation of the data, which will take place during the 59th ASH Annual Meeting, to be held in Atlanta, December 9-12.